Amgen Inc. (AMGN) — Stock Price, Chart & Analysis
Amgen Inc. (AMGN) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $221.79B and a trailing P/E ratio of 24.39. Over the past 52 weeks, AMGN has traded between $269.77 and $447.03. Amgen Inc. pays a dividend yielding 2.6%. View the live AMGN chart, technical opinion, analyst ratings, fundamentals and latest news below.
Amgen Inc. (AMGN) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $221.79B |
| P/E ratio (TTM) | 24.39 |
| EPS (TTM) | $16.82 |
| Dividend yield | 2.6% |
| 52-week high | $447.03 |
| 52-week low | $269.77 |
| Beta | 0.43 |
| Avg. volume | 2.65M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about Amgen Inc. (AMGN)
How much does one share of Amgen Inc. cost?
As of the latest update, one share of Amgen Inc. (AMGN) trades at $100 (+0.00% today).
What is Amgen Inc.'s market cap?
Amgen Inc. has a market capitalization of approximately $221.79B.
What is Amgen Inc.'s P/E ratio?
Amgen Inc. has a trailing price-to-earnings (P/E) ratio of 24.39.
What is Amgen Inc.'s earnings per share (EPS)?
Amgen Inc.'s trailing twelve-month EPS is $16.82.
Does Amgen Inc. pay a dividend?
Yes — Amgen Inc. pays a dividend with a yield of 2.6% ($10.08 per share annually).
What is Amgen Inc.'s 52-week trading range?
Over the past year, AMGN has traded between $269.77 and $447.03.
What is the analyst price target for Amgen Inc.?
The mean analyst price target for Amgen Inc. is $387.69. This is informational only and not investment advice.
Latest Amgen Inc. (AMGN) news
- Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses VeevaNews · Sep 23, 2026
- Stock Market Today: Dow Skids But Apple Eyes A Buy Point; Filing Says Trump Makes These TradesNews · Sep 22, 2026
- Amgen Boasts Success In Sjogren's; Shares Charge AheadNews · Sep 22, 2026
- Sector Update: Healthcare Stocks Rise Late AfternoonNews · Sep 22, 2026
- Amgen reports a Phase 3 win with Sjögren’s drug candidateNews · Sep 22, 2026
- AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’News · Sep 22, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live AMGN dashboard…